Re-investigating PLK1 inhibitors as antimitotic agents
Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitot...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-11-01
|
| Series: | Molecular & Cellular Oncology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/23723556.2017.1356430 |
| _version_ | 1797677183852871680 |
|---|---|
| author | Quentin Delacour Olivier Gavet |
| author_facet | Quentin Delacour Olivier Gavet |
| author_sort | Quentin Delacour |
| collection | DOAJ |
| description | Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitotic arrest and death of cancer cells. |
| first_indexed | 2024-03-11T22:41:22Z |
| format | Article |
| id | doaj.art-f7e9f59955834e89a22927d48aded059 |
| institution | Directory Open Access Journal |
| issn | 2372-3556 |
| language | English |
| last_indexed | 2024-03-11T22:41:22Z |
| publishDate | 2017-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Molecular & Cellular Oncology |
| spelling | doaj.art-f7e9f59955834e89a22927d48aded0592023-09-22T09:10:58ZengTaylor & Francis GroupMolecular & Cellular Oncology2372-35562017-11-014610.1080/23723556.2017.13564301356430Re-investigating PLK1 inhibitors as antimitotic agentsQuentin Delacour0Olivier Gavet1Centre National de la Recherche ScientifiqueSorbonne Universités, UPMC University Paris 06Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitotic arrest and death of cancer cells.http://dx.doi.org/10.1080/23723556.2017.1356430polo-like kinase 1kinase inhibitorantimitoticg2 phasecancer |
| spellingShingle | Quentin Delacour Olivier Gavet Re-investigating PLK1 inhibitors as antimitotic agents Molecular & Cellular Oncology polo-like kinase 1 kinase inhibitor antimitotic g2 phase cancer |
| title | Re-investigating PLK1 inhibitors as antimitotic agents |
| title_full | Re-investigating PLK1 inhibitors as antimitotic agents |
| title_fullStr | Re-investigating PLK1 inhibitors as antimitotic agents |
| title_full_unstemmed | Re-investigating PLK1 inhibitors as antimitotic agents |
| title_short | Re-investigating PLK1 inhibitors as antimitotic agents |
| title_sort | re investigating plk1 inhibitors as antimitotic agents |
| topic | polo-like kinase 1 kinase inhibitor antimitotic g2 phase cancer |
| url | http://dx.doi.org/10.1080/23723556.2017.1356430 |
| work_keys_str_mv | AT quentindelacour reinvestigatingplk1inhibitorsasantimitoticagents AT oliviergavet reinvestigatingplk1inhibitorsasantimitoticagents |